Piper Sandler Lowers Akebia Therapeutics (AKBA) PT to $4 as Firm Updates Estimates Following Year-End Reports

Core Viewpoint - Akebia Therapeutics Inc. is identified as a promising growth stock for the next 20 years, despite recent adjustments in price targets by analysts [1]. Financial Performance - In Q3, Akebia reported total revenue of $58.8 million and a net income of $540,000, marking a significant turnaround from a net loss of $20 million in Q3 2024 [2]. - The revenue from the dialysis drug Vafseo was lower than expected at $14.3 million due to operational challenges, but the company expanded patient access to 70,000 and achieved over 700 active prescribers [2]. Future Outlook - Management anticipates a temporary revenue dip in Q4 due to inventory adjustments at US Renal Care, but projects growth to resume in Q1 2026 [3]. - The company is focused on its 2026 pipeline, including the initiation of a Phase 2 study for rare kidney diseases, and asserts that current cash reserves are adequate to support its path to sustained profitability [3].